These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 33741032)

  • 61. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
    Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.
    AmeliMojarad M; AmeliMojarad M; Cui X
    Pathol Res Pract; 2023 Apr; 244():154338. PubMed ID: 36905697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
    Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
    Li F; Chen Y; Pang M; Yang P; Jing H
    Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
    Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.
    Lee DY; Im E; Yoon D; Lee YS; Kim GS; Kim D; Kim SH
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1033-1057. PubMed ID: 33301862
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
    Shan J; Han D; Shen C; Lei Q; Zhang Y
    Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
    Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
    Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
    Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting novel inhibitory receptors in cancer immunotherapy.
    Ding QQ; Chauvin JM; Zarour HM
    Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.